The artificial insemination market is projected to register a CAGR of 8.9% from 2024 to 2032 to reach approximately USD 9.2 billion by 2032. Artificial insemination is an assisted reproductive treatment in which semen containing living sperm is introduced into a female's cervix, fallopian tubes, or uterus. It is accomplished through short and relatively painless artificial insemination homologous (AIH) or artificial insemination donor semen (AID) procedures. Self-insemination kits are now available on the market and can be used in the comfort of one's home.Â
Artificial insemination is now widely used in animal breeding to improve reproductive success and conserve threatened or endangered species. It also prevents the spread of certain diseases and sterility in animals due to genital conditions. For instance, Genus's plc, a leading animal genetics firm, collaborated with Beijing Capital Agribusiness Co. Ltd, a leading Chinese animal protein genetics firm, to research and develop virus-resistant techniques in pigs. The market expansion is fueled by major pharmaceutical firms' aggressive development of medications undergoing clinical and preclinical testing, as well as their introduction of new insemination kits with proven potential benefits. In addition, rising rates of infertility among the world's population are significantly expanding the demand for artificial insemination.
COVID-19 Impact Analysis
Since its discovery in December 2019, the COVID-19 virus has spread to almost every nation, causing the World Health Organization (WHO) to declare it a public health emergency. A brand-new coronavirus called COVID-19 was found to be the cause of the pneumonia cases. This virus quickly spread throughout the world, killing many people. The World Health Organization (WHO) declared COVID-19 a  pandemic in March 2020, and strict measures were recommended to prevent the disease's spread. Since then, the pandemic has slowed healthcare sector expansion and disrupted the supply chain. Furthermore, governments in several countries imposed nationwide lockdowns to halt the spread of COVID-19.
In February 2024
, PIC has partnered with HKScan Sweden to enhance its Hampshire pig breed by accessing PIC’s expertise and cutting-edge technology.
In March 2023
, URUS introduced the Dairy Genetics Multiplication Program in African countries such as Uganda, Kenya, and Tanzania; this move is expected to spur small-scale AI adoption among farmers, create a reliable network of AI technicians, and form partnerships with local stakeholders. Key market participants also implement similar moves that have caused much increased regional expansion activities within the industry.
CRV has partnered with Bullwise - an Irish breeding organization in January 2023 – for the distribution of CRV genetic solutions across Ireland & Northern Ireland, thus giving farmers access to quality semen from top bulls. This made BullWise one of the largest distributors of CRV in that region.
For instance, in October 2022, Genus extended its partnership with Tropic - an Agri-biotech company, to apply the latter’s Gene Editing, Gene Silencing (GEiGS) technology in bovine and swine genetics. The market is full of continuous improvements aimed at optimizing reproductive processes, enhancing genetic diversity and adapting to emerging challenges in animal breeding.
The central government of India approved over 400 mobile veterinary units in Madhya Pradesh in April 2022. For example, every vehicle will be equipped with veterinary instruments like minor surgical facilities and artificial insemination apparatus, together with all other requirements
In April 2022
 central government sanctioned more than four hundred mobile veterinary units for about four point six million livestock mainly found across Madhya Pradesh state in India. Vehicle equipment will include vet tools as well as those for minor surgery and artificial insemination.
In January 2022
, Semex announced it would continue its successful partnership with Nedap. The extended agreement allows the ai24® program from Semex to be available in additional countries.
LIC established a laboratory for sexed semen services within their operation in September 2021. The facility helped carry out artificial insemination of about four and a half million cows during the spring breeding season.
Tecnovet, SL, a Spanish company that specializes on swine artificial insemination technology and other veterinary products, was acquired by IVM Technologies in December 2020.
Cogent and AB Europe introduced an innovative sexed semen service for UK sheep farmers in August 2020.
Cogent launched a new sexed semen service for sheep producers in the United Kingdom in August 2020 through its partnership with AB Europe, a player in the sheep breeding industry.
Merck Animal Health purchased IdentiGEN from MML Growth Capital Partners, Ireland, in August 2020.
Zoetis also bought Benchmark Holdings PLC, which is engaged into developing and commercializing fish vaccines as well as providing vaccinations and diagnostics for aquaculture services in July 2020.
Rising infertility rates and increased awareness among individuals about alternative reproductive treatments are two major factors influencing the market. Furthermore, governments in many countries have legalized same-sex marriage and provided insurance coverage to civil unions for artificial insemination procedures, fueling the market growth. Aside from that, the growing  population and increasing demand for animal-based protein drive the demand for artificial insemination in domestic livestock animals. Improving veterinary services and rising
expenditure drive market growth. Furthermore, the leading players are forming strategic alliances to expand their portfolio of animal genetics and strengthen their position in various markets.
 Market Drivers
Infertility is one of the most serious and widespread issues affecting today's youth worldwide. The female preference for pregnancy and the gradual increase in the number of infertile couples who require pregnancy assistance can be attributed to market growth. The age of women, the quality of their eggs, and women in their late 30s are expected to increase demand for artificial insemination. Furthermore, infertility affects over 20 million women, according to the National Women's Health Resource Center. Total fertility is expected to fall from 2.43 to 2.39 children per woman between 2020 and 2030, according to the 2017 United Nations World Population Prospects report. The rising prevalence of infertility among the  population drives the  market forward.
Market Restraints:
Most countries' stringent regulations governing who is eligible to receive fertility treatments are impeding the growth of the  market. Italy and France, for example, prohibit lesbian couples and single women from using artificial insemination. Italy and Austria are among the countries that have banned all sperm and egg donations for IVF. Norway and Germany prohibit egg donation but permit sperm donation.
Market Opportunities:
Many insurance companies now cover artificial insemination as a medical procedure. These initiatives assist patients in fighting infertility and creating opportunities in the insurance industry. Moreover, Governments and international organizations develop policies and establish new institutions to improve medical connectivity, such as the Assisted Reproductive Technology (ART) Regulation Bill, the Nation Public Action Plan, the National Family Policy, and other initiatives. According to the UN Security Council, 84% of the country supports the policy that directly and indirectly affects the country's infertility.
The market segments of artificial insemination, based on type, is intrauterine, intracervical, and intratubal. The intrauterine segment is expected exhibit a rapid CAGR and hold the largest market share in the artificial insemination market growth in 2021. This insemination method is the most used to treat infertility because it produces the highest pregnancy rate. It is also a non-invasive procedure. During the washing process, prostaglandins, pathogenic agents, antigenic proteins, nonmotile spermatozoa, immature germ cells, and other contaminants are removed, resulting in high-quality sperm. These are the primary benefits that will drive the intrauterine segment's growth in the  market during the forecast period. The intravaginal portion is expected to be the second largest (IVI). IVI can be performed in a fertility clinic or home, which is especially beneficial for surrogacy and donor insemination.
Artificial Insemination End-User Insights
The artificial insemination market segmentation, by type, is hospitals & clinics, fertility centers, and home-based. The fertility center segment is expected to have the largest market share in 2021 and to register the fastest CAGR during the forecast period. Fertility clinics are implementing various strategies to increase customer awareness and knowledge about available treatments and solutions for
problems. Because of the rise in infertility rates worldwide, several medical centers focus on providing infertility treatment. These are the major key factors driving the fertility clinics & other facilities segment's growth during the forecast period.
the artificial insemination market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. Europe accounted for the most extensive market share. Asia-Pacific will exhibit the highest CAGR during the forecast period.
Asia-Pacific dominated the  market in 2021 because of rising mortality rates and increased awareness about available treatment options. Asia Pacific is expected to be the fastest-growing business sector in the coming years. A growing number of regional players offering managed impregnation units requiring little to no effort in countries such as China is expected to aid market development in the APEJ region through 2026. Furthermore, factors such as a high rate of unnatural birth cycles and fruitlessness in the location, for example, because of the disturbing levels of air pollution in China, have resulted in a decrease in sperm count, quality, and motility, driving the interest in manual sperm injection in APEJ.
Europe is anticipated to grow at a significant rate over the forecast period. Postponement of pregnancy and lifestyle changes are two factors contributing to this decrease. Due to factors including the availability of reimbursement, the market in Europe is predicted to grow throughout the forecast period. Additionally, a highly developed healthcare infrastructure and quick uptake of cutting-edge products and technology are anticipated to affect the market in Europe favorably.
 Artificial Insemination Market Competitive Landscape
The market includes tier-1, tier-2, and local players. The tier-1 and tier-2 players have  reach with diverse product portfolios. Companies such as Vitrolife AB, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical dominate the  market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are concentrating on supporting research and development. Furthermore, they embrace strategic growth initiatives, such as development, product introduction, joint ventures, and partnerships, to strengthen their market position and capture an extensive customer base.
Prominent players in the artificial insemination market research areÂ
Objectives of the Study
The objectives of the study are summarized in 5 stages. They are as mentioned below:
To identify and estimate the market size by type and end-user by value (in US dollars). Also, to understand the consumption/ demand created by consumers during the forecast period 2024 - 2032.
To identify and infer the drivers, restraints, opportunities, and challenges in the market growth of artificial insemination
To find out the factors which are affecting the market size of artificial insemination among consumers
To identify and understand the various factors involved in the market affected by the pandemic
To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Intended Audience
| Attribute/Metric | Details |
| Market Size 2023 | N/A (USD Billion) |
| Market Size 2024 | N/A (USD Billion) |
| Market Size 2032 | 9.2 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 8.9 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Geographies Covered | Â North America, Europe, Asia-Pacific, and the Rest of the World (RoW) |
| Key Vendors | Vitrolife AB, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical |
| Key Market Opportunities | Insurance companies covering artificial insemination treatment under medical coverage |
| Key Market Drivers | Rising infertility issues in people to aid the  market growth |
Artificial insemination Market Highlights:
Frequently Asked Questions (FAQ) :
The artificial insemination market forecast period is 2024 - 2032
The market is expected to register a CAGR of 8.9% over the next 10 years, according to artificial insemination market research.
Asia-Pacific is expected to register the highest CAGR during 2024 - 2032
Europe held the largest share in 2021
The market size is expected to be USD 9.2 billion by 2032.
Vitrolife AB, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical are the major companies operating in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
